SINO BIOPHARMACEUTICAL News

Sino Biopharmaceutical Limited Goes Ex Dividend Tomorrow

Seeking AlphaJun 11 08:45 ET

Sino Biopharmaceutical's Phase 2 Trial Results of Lung Cancer Tablet Published in Medical Journal

The results of Sino Biopharmaceutical's (HKG:1177) phase 2 trial for its garsorasib tablet have been published on medical journal The Lancet Respiratory Medicine, according to a Tuesday filing with th

MT NewswiresJun 11 05:32 ET

SINO BIOPHARMACEUTICAL To Go Ex-Dividend On June 11th, 2024 With 0.00385 USD Dividend Per Share

June 10th - $SINO BIOPHARMACEUTICAL(SBMFF.US)$ is trading ex-dividend on June 11th, 2024. Shareholders of record on June 12th, 2024 will receive 0.00385 USD dividend per share on July 5th, 2024. T

moomoo NewsJun 9 21:00 ET

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 48% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Sino Biopharmaceutical fair value estimate is HK$5.41 Current share price of HK$2.84 suggests Sino Biopharmaceutical is potentially 48% under

Simply Wall StJun 6 19:06 ET

Sino Biopharmaceutical Presents Findings of Anti-Tumor Drug at American Cancer Conference

Sino Biopharmaceutical (HKG:1177) unit invoX Pharma orally presented updated findings from an ongoing phase 1 study of FS222 at the 2024 annual meeting of the American Society of Clinical Oncology, a

MT NewswiresJun 5 07:56 ET

Sino Biopharmaceutical Cuts Conversion Price of Euro-Denominated Bonds Due 2025

Sino Biopharmaceutical (HKG:1177) will slash the conversion price of its 750 million euros zero-coupon convertible bonds due 2025 to HK$11.86 from HK$12.06 per share on June 19, according to a Wednesd

MT NewswiresJun 5 07:21 ET

Sino Biopharmaceutical: Li Mingqin Retired as Executive Director

Sino Biopharmaceutical: Li Mingqin Retired as Executive Director

Dow JonesJun 5 04:42 ET

Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials

Sino Biopharmaceutical (HKG:1177) said a multi-center Phase III clinical study on Benmelstobart Injection in combination with Anlotinib Hydrochloride Capsules as a first-line treatment of advanced unr

MT NewswiresMay 24 01:15 ET

Sino Biopharmaceutical's Breakthrough in Renal Cancer Treatment

TipRanksMay 23 07:37 ET

Sino Biopharmaceutical Limited's (HKG:1177) P/E Is Still On The Mark Following 26% Share Price Bounce

Those holding Sino Biopharmaceutical Limited (HKG:1177) shares would be relieved that the share price has rebounded 26% in the last thirty days, but it needs to keep going to repair the recent damage

Simply Wall StMay 22 03:54 ET

Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%

Sino Biopharmaceutical (HKG:1177) said its category 1 innovative drug Benmelstobart Injection obtained approval for marketing from China's National Medical Products Administration (NMPA) as a first-li

MT NewswiresMay 9 03:44 ET

Insiders Hold 49% of Sino Biopharmaceutical Limited (HKG:1177), and They've Been Buying Recently

Key Insights Significant insider control over Sino Biopharmaceutical implies vested interests in company growth A total of 5 investors have a majority stake in the company with 52% ownership Rece

Simply Wall StMay 6 21:00 ET

Executive Chairwoman of the Board of Sino Biopharmaceutical Y. Y. Tse Buys 167% More Shares

Those following along with Sino Biopharmaceutical Limited (HKG:1177) will no doubt be intrigued by the recent purchase of shares by Y. Y. Tse, Executive Chairwoman of the Board of the company, who spe

Simply Wall StApr 21 20:30 ET

Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug

Sino Biopharmaceutical's (HKG:1177) key clinical research for the registration of Rovadicitinib has met its primary endpoint, a Thursday filing on the Hong Kong bourse stated. The pharmaceutical compa

MT NewswiresApr 19 04:15 ET

Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024

Sino Biopharmaceutical (HKG:1177) presented Phase-II Clinical Trial results for its new drug for non-small cell lung cancer (NSCLC) at the annual meeting of the American Association for Cancer Researc

MT NewswiresApr 10 20:20 ET

News Flash: 22 Analysts Think Sino Biopharmaceutical Limited (HKG:1177) Earnings Are Under Threat

One thing we could say about the analysts on Sino Biopharmaceutical Limited (HKG:1177) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for

Simply Wall StApr 8 19:09 ET

Sino Biopharmaceutical Trustee Repurchases Shares

A trustee of Sino Biopharmaceutical (HKG:1177) bought back a further 6.8 million shares under its share award scheme for around HK$19.1 million or HK$2.83 apiece, a Monday filing on the Hong Kong bour

MT NewswiresApr 8 06:38 ET

Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China

Sino Biopharmaceutical (HKG:1177) will develop and commercialize Boehringer Ingelheim's cancer treatments in mainland China under a strategic partnership agreement. The Chinese pharmaceutical company'

MT NewswiresApr 8 05:42 ET

Bullish Sino Biopharmaceutical Insiders Loaded Up On CN¥133.6m Of Stock

Over the last year, a good number of insiders have significantly increased their holdings in Sino Biopharmaceutical Limited (HKG:1177). This is encouraging because it indicates that insiders are more

Simply Wall StApr 6 20:29 ET